Form 8-K

8-K — BioAtla, Inc.

Accession: 0001539497-26-002373

Filed: 2026-08-28

Period: 2026-08-26

CIK: 0001826892

SIC: 2836 (BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES))

Item: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Documents

8-K — n5620_x8-8k.htm (Primary)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: n5620_x8-8k.htm · Sequence: 1

false

0001826892

2026-08-26

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 26, 2026

BIOATLA,

INC.

(Exact name of Registrant as Specified

in Its Charter)

Delaware

001-39787

85-1922320

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

11085 Torreyana Road

San Diego, California

92121

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: 858 558-0708

(Former Name or Former Address, if Changed

Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended

to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

BCAB

The

Nasdaq Capital Market

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01. Notice

of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As previously

disclosed, on February 6, 2026, BioAtla, Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”)

indicating that the Nasdaq Hearings Panel (the “Panel”) had determined to suspend the Company’s securities from Nasdaq

(the “Delist Determination”) based upon (i) the Company’s non-compliance with the $1.00 bid price requirement under

Nasdaq Listing Rule 5550(a)(2) and (ii) the Company’s failure to demonstrate compliance with the $2.5 million stockholders’

equity requirement under Nasdaq Listing Rule 5550(b)(1), the latter notwithstanding the Company’s prior compliance with the alternative

threshold of $35 million in market value of listed securities under Nasdaq Listing Rule 5550(b)(2) for 69 consecutive trading days. Immediately

upon receipt of the Delist Determination, and in accordance with Nasdaq Listing Rule 5820(b), the Company submitted a request to the Nasdaq

Listing and Hearing Review Council (the “Listing Council”) that the Listing Council call for immediate review of the Delist

Determination and stay any suspension or delisting action pending completion of the Listing Council’s review. The Company was notified

on February 8, 2026, that the Listing Council had determined to call for review the Delist Determination. In rendering its decision, the

Listing Council also determined to stay any suspension and delisting action pending the outcome of the Listing Council’s review.

On August

26, 2026, the Listing Council notified the Company that it had issued a decision affirming the prior determination of the Panel to delist

the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq.

As a

result of the Listing Council’s decision, the Common Stock is subject to delisting from Nasdaq. Unless the Nasdaq Board calls the

matter for review in its sole discretion pursuant to Nasdaq Listing Rule 5825, trading of the Common Stock on Nasdaq will be suspended

at the opening of business on August 31, 2026, and a Form 25-NSE will be filed with the Securities and Exchange Commission (the “SEC”)

to remove the Company’s securities from listing and registration on Nasdaq following the Nasdaq Board’s determination

not to call the Listing Council decision for review.

Once

the Common Stock is suspended from trading on Nasdaq, the Company expects that the Common Stock would be immediately eligible for quotation

on the OTC Markets system under its current trading symbol: BCAB, which may have a material adverse effect on the trading price and volume

for the Common Stock. There can be no assurance that a market for the Common Stock will develop or be maintained on the OTC Markets system,

and the Company’s stockholders may find it more difficult to buy or sell their shares.

In addition,

the Company’s formal process initiated in March 2026 to explore and evaluate strategic options to maximize shareholder value is

ongoing. There can be no assurance that this process will result in any additional agreements or transactions. The Company will provide

a further update when the Company’s Board of Directors approves a specific action or when the Company determines disclosure is appropriate

or required.

Forward-Looking Statements

This Current Report

on Form 8-K (this “Current Report”) contains forward-looking statements. All statements other than statements of historical

facts contained herein, including, but not limited to, statements the Company makes regarding the anticipated suspension of trading and

delisting of the Common Stock on Nasdaq, the Company’s eligibility to trade on the OTC Markets system and the ongoing strategic

process are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor

provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties,

and other important factors that may cause the Company’s actual results, performance, or achievements to be materially different

from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties

include, among others, the Company’s ability to continue as a going concern and that it will need additional funding to continue

development of its CAB technology platform and its CAB product candidates; whether the Company will be able to pursue a strategic transaction,

or whether any transaction, if pursued, will be completed on attractive terms or at all; the risk that preliminary or interim clinical

results may not be indicative of results from later cohorts or larger populations; potential delays in clinical and preclinical trials;

the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or

completion dates for clinical trials, regulatory submission dates, or regulatory approval dates, as well as the possibility of unfavorable

new clinical data and further analyses of existing clinical data; whether regulatory authorities will be satisfied with the design of

and results from the clinical studies or take favorable regulatory actions based on results from the clinical studies; the Company’s

dependence on the success of its CAB technology platform; its ability to enroll patients in its ongoing and future clinical trials; the

successful selection and prioritization of assets to focus development on selected product candidates and indications; the Company’s

ability to form collaborations and partnerships with third parties and the success of such collaborations and partnerships; the Company’s

reliance on third parties for the manufacture and supply of its product candidates for clinical trials; the Company’s reliance

on third parties to conduct its clinical trials and some aspects of its research and preclinical testing; and potential adverse impacts

due to geopolitical or macroeconomic events outside of its control, including health epidemics or pandemics. For a description of additional

risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as

risks relating to the Company’s business in general, see the risk factors set forth in the Company’s Quarterly Report on

Form 10-Q filed with the SEC on August 13, 2026 and subsequent filings with the SEC. Any forward-looking statements contained

in this Current Report speak only as of the date hereof, and the Company specifically disclaims any obligation to update any forward-looking

statement, whether as a result of new information, future events or otherwise.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of

1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioAtla, Inc.

Date:

August 28, 2026

By:

/s/ Christian Vasquez

Christian Vasquez

Chief Financial Officer

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 6

v3.26.1

Cover

Aug. 26, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Aug. 26, 2026

Entity File Number

001-39787

Entity Registrant Name

BIOATLA,

INC.

Entity Central Index Key

0001826892

Entity Tax Identification Number

85-1922320

Entity Incorporation, State or Country Code

Entity Address, Address Line One

11085 Torreyana Road

Entity Address, City or Town

San Diego

Entity Address, State or Province

Entity Address, Postal Zip Code

92121

City Area Code

858

Local Phone Number

558-0708

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Stock, $0.0001 par value per share

Trading Symbol

BCAB

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration